Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-αvβ6-BP PET Imaging in Breast, Colorectal, Lung, or Pancreatic Cancer
NCT03164486Phase 1Active, not recruiting
- Start
- Nov 2016
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-αvβ6-BP in breast cancer, colorectal cancer (CRC), lung cancer and 1 more. Primary endpoint: Assessment of safe administration of 18F-αvβ6-BP at 6 months. Started Nov 2016; status: active, not recruiting.
02
Drugs
18F-αvβ6-BP
03
Conditions
breast cancercolorectal cancer (CRC)lung cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03164486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164486.